Shanghai Biopharmaceutical Fund
Huangpu, Shanghai, China
Overview
Shanghai Biomedical Industrial Equity focuses on areas that are in line with the development strategy of the biomedical industry.
- Total investments
- 3
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Finance
- Financial Services
- Impact Investing
Investment portfolio
- AccuPulse
Led · Series A · Feb 2024
AccuPulse focuses on cardiac electrophysiology and structural heart interventional devices, offering an integrated product matrix that includes a pulsed field ablation (PFA) system, an AI-driven 3D mapping system, and a range of consumables such as high-density mapping catheters and transseptal tools. Its AccuPulse PFA system consists of a disposable PFA catheter (AccuPulse®) and a multi-channel generator (AccuBlator®), and achieved immediate intraoperative pulmonary vein isolation of 100% with a 12-month success rate of 87.7% in reported follow-up data. The PFA system received NMPA special approval in May 2025, marking the company’s transition from R&D to commercialization; the firm is concurrently advancing registration studies for its 3D mapping platform. The 3D system integrates magnetic-electric localization with intracardiac ultrasound and uses neural-network–based 3D model registration, positioning it as one of the few AI-driven ultrasound-magnetic-electric mapping solutions globally. AccuPulse has pursued clinical outreach across 16 provinces, secured Beijing procurement wins, and established strategic collaborations with partners including Shanghai Pharmaceuticals and Taimei Medical. The company operates R&D centers in China and the U.S., and its leadership team comprises industry veterans from major global medtech firms.
- Meditrust
Participated · Series C · Aug 2021
MediTrust is a Shanghai-based private healthcare payor founded in 2017 and led by founder and CEO Seth Zhang. It leverages proprietary integrated platforms to serve healthcare and insurance companies, delivering comprehensive healthcare products and services aimed at lowering medical costs. A core service, Care2Pay, partners with more than 50 pharmaceutical and insurance companies and over 2,000 DTP pharmacies, with national coverage in over 400 cities. Care2Pay enables millions of patients with cancer, chronic, and rare diseases to access innovative drugs more affordably; in the first half of 2021 it helped patients and families save over RMB300 million in healthcare expenditures. MediTrust also collaborates with insurers to launch municipal health insurance products in more than 40 cities, including Beijing and Shanghai, and has been instrumental in Shanghai’s Huhuibao coverage expansion.
Team
No current team members are available.